Xu Yaochang is the founder of Abbisko Therapeutics. Abbisko Therapeutics has raised $28M in total funding. Latest round: Series A. Based in Shanghai, China.
Yao-Chang Xu is the founder and CEO of Abbisko Therapeutics, a Shanghai-based startup established in 2016. The company focuses on developing immuno-oncology drugs, particularly small-molecule drugs for cancers prevalent in Asian patient populations, and also has early-stage programs in liver disease, viral infections, and CNS disorders. Abbisko Therapeutics successfully raised $28 million in Series A financing to advance its cancer immunotherapies into clinical trials and establish R&D teams and discovery centers. Xu, an industry veteran with 25 years of experience, previously served as general manager at Hansoh BioMedical and held executive roles at Novartis Institutes for BioMedical Research and Eli Lilly.
Full founder directory · Investor directory · Company funding database · Fundraising library